The real costs of the new Alzheimer's drug, Leqembi — and why taxpayers will foot much of the bill - CBS News
cbsnews.comSubmitted by cbsnews1121 in health
Medicare could shell out more than $100,000 a year per patient to cover the drug and the complex scans and tests needed to monitor its potentially lethal risks for patients.